



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

April 20, 2012

Via E-mail

Peter A. Thompson
Chief Executive Officer
Response Biomedical Corp.
1781 - 75th Avenue W.
Vancouver, British Columbia
Canada V6P 6P2

**Re: Response Biomedical Corp.
Form 20-F for the Fiscal Year Ended December 31, 2010
Amended November 9, 2011
File No. 0-50571
Response Letters Dated April 2, 2012 and April 18, 2012**

Dear Dr. Thompson:

We refer you to our comment letters dated March 6, 2012 and April 11, 2012, regarding business contacts with Cuba, Iran, Sudan, and Syria. We have completed our review of this subject matter. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Cecilia Blye

Cecilia Blye, Chief
Office of Global Security Risk

cc: John Reynolds
Assistant Director
Division of Corporation Finance